Fragile X Syndrome Lacks Efficient Treatment Options, States Black Swan Analysis in Its In-demand Report Published at MarketPublishers.com
30 Nov 2016 • by Natalie Aster
LONDON – Fragile X syndrome (Fragile X, or FXS) is the main cause of inherited mental problems, autism and deficiency of intellect, and is the second major cause of genetic developmental disabilities, after Down syndrome (trisomy 21). It is estimated that FXS affects close to 1 in 2500-4000 men and 1 in 7000-8000 women. The prevalence of carrier status among women is estimated at 1 in 130-250 population; while the prevalence of carrier status amid men stands at 1 in 250-800 population.
To date, neither cure nor any definitive treatment options for FXS are available; among the therapies are those assisting the individual in reaching their maximal potential by way of education; therapies like speech, behavioral, language, and physical; and other treatment modalities. Fragile X detects FMR1 DNA.
Drug therapy may only help some individuals with selected grave problems, and the medications should be prescribed only by doctors; so far there is no medication capable of curing FXS.
Adults with FXS may take advantage of a team approach to help patients adapt to independent living, if there is a possibility.
Comprehensive research report “Epiomic Epidemiology Series: Fragile X Syndrome Forecast in 11 Major Markets 2016-2026” drawn up by Black Swan Analysis provides reliable information on today’s prevalent population for FXS across top 11 markets such as the USA, Germany, France, Brazil, Spain, the UK, Australia, Italy, Japan, China and India; the data are broken down by 5-year age cohort and gender. Alongside the current prevalence, the study also gives insights into risk factors for heart disease, diagnosis and prognosis of the disease, along with particular variations by geographic region and ethnicity. It identifies a number of the main symptoms and co-morbidities of FXS, alongside providing trustworthy data on overall prevalence. The report provides insights and long-term forecasts into sub-populations suffering from the disease across various countries.
More comprehensive research reports by the publisher can be found at Black Swan Analysis page.